Search Main menu LEO Pharma Patients Therapeutic areas Products Research and Development Partnering Careers Section menu Management Organisation Mission & Vision Values Business Ethics Positions and views Global presence The LEO Foundation LEO Pharma Research Foundation History Media centre News News 2015 News 2014 News 2013 News 2012 News 2011 News 2010 News 2009 Downloads Social media Financial figures LEO Innovation Lab LEO Pharma strengthens global leadership to accelerate entry into biologics in dermatology LEO Pharma, a global healthcare company dedicated to helping people achieve healthy skin, announces changes to its global leadership team. The changes are designed to strengthen LEO Pharma’s entry into biologics in dermatology. BALLERUP, 13 September 2016 – LEO Pharma today announced changes to its global leadership team. The changes come just a few months after the company signed a USD 1 billion partnership with AstraZeneca covering potential new biologic medicines for two of the world’s major skin diseases, atopic dermatitis and psoriasis, where a significant unmet medical need remains. “Now that we have successfully expanded our dermatology portfolio beyond topical treatments to include biologics, our next step is to build our competencies within biologics. The changes to our global leadership announced today will help our entry into the biologics market, where there is a high unmet need amongst people with skin diseases,” says LEO Pharma President and CEO Gitte Aabo. New global leadership team Guillaume Clément is appointed Executive Vice President, Region EUROPE+. Guillaume Clément joined LEO Pharma in 2009 and recently held the position of Vice President, Area France, Canada and Belgium. To realise the potential of future launches in the US, a recruitment process has been initiated for a new Executive Vice President for Region US. LEO Pharma expects to bring a potential new biological treatment in atopic dermatitis to the US as the first market. Barbara Osborne, former Executive Vice President Region US, will leave the company. Patrice Baudry is appointed Senior Vice President of Global Strategy & Portfolio Management, a new global function that merges Global Strategy & Business Development with Global Commercial Strategy. From today, LEO Pharma’s global leadership team comprises the following functions and leaders: President and CEO Gitte Aabo Region EUROPE+, Executive Vice President Guillaume Clément Region INTERNATIONAL, Executive Vice President Joergen Damsbo Andersen Region US, Executive Vice President Joergen Damsbo Andersen (interim) Global Research & Development, Executive Vice President Kim Kjoeller Global Finance, IT and Legal, Executive Vice President Anders Kronborg Global People & Communications, Senior Vice President Mette Vestergaard Global Product Supply, Senior Vice President Jim McPherson Global Strategy & Portfolio Management, Senior Vice President Patrice Baudry. All Executive Vice Presidents and Senior Vice Presidents report to the CEO. Contact media relations Henrik Steen Heskjaer Kyndlev Corporate Communications Manager hdtdk@leo-pharma.com TEL +45 7226 3399 Eva Juul Langlands Corporate Communications Manager ejldk@leo-pharma.com TEL +45 7226 2059 Footer menu News Global presence Contact Terms of use Clinical Trial Disclosure LEO Pharma A/S Industriparken 55 DK-2750 Ballerup Danmark CVR No. 56759514 Tel +45 4494 5888 Fax +45 7226 3321 Which site would you like to visit? We use cookies on this website The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information. By continuing to browse our website, you are agreeing to our use of cookies If you want to know more about our cookie policy and how to avoid and delete cookies click here.